From Bio
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
From Bio makes health supplements, vitamins, functional foods, and similar wellness products, for everyday consumers in South Korea and abroad.
It supplies these products directly to consumers through home-shopping channels, its own online store, and other digital platforms. Listed on KOSDAQ, Korea's tech and small-cap board, the company covers the full production chain in-house, from sourcing raw ingredients and developing functional formulas to manufacturing and distribution. Beyond supplements, it also conducts research into cell-culture and stem-cell technologies, and operates a separate cosmetics business.
Summary is AI-generated and may contain errors · figures from DART filings
From Bio holds proprietary functional-ingredient approvals granted directly by Korea's Ministry of Food and Drug Safety, which underpin its core branded supplement products.
From Bio in five facts
What does From Bio do?
From Bio makes health supplements, vitamins, functional foods, and similar wellness products, for everyday consumers in South Korea and abroad.
Where is From Bio listed and in which sector?
From Bio (Korean name: 프롬바이오) trades under KRX code 377220 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Consumer Staples sector, Food & Beverage.
How large is From Bio?
Its market capitalisation was US$10.1M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were From Bio's latest annual revenue and operating profit?
For fiscal year 2025, From Bio reported revenue of US$54.5M, an operating loss of US$14M and a net loss of US$17.5M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 7.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Other market noticeOct 7
- Shareholder register closure / record date setOct 2
- Resolution to convene a general shareholders' meeting (extraordinary meeting)Oct 2
- Report on large shareholdings (5% rule) (standard)Sep 18
- Report on securities held by executives/major shareholdersSep 18
- Other market noticeSep 16
- Trading suspension (share consolidation/split registration)
KOSDAQ trading in From Bio common shares will be suspended from July 20, 2026 until the day before the share-consolidation re-listing date, due to a change in electronic registration from a share consolidation.
M&A · Jul 14